← TrialMatch
HomeTrials

Improve Cancer-related Cognitive Impairment

Cancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and/or hormonal treatments. This application focuses on evaluating if using a cognitive mobile training application can decrease th

Condition(s)Gynecologic Cancer, Chemotherapy Effect, Chemo-brain, Cancer-related Cognitive Difficulties
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryCancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and/or hormonal treatments. This application focuses on evaluating if using a cognitive mobile training application can decrease the impact of CRCI in gynecologic oncology patients through a multidisciplinary approach with patients undergoing assessments by our neurocognitive team.
Who can participateInclusion criteria are: * newly diagnosed gynecologic malignancy (uterine, cervical, ovarian, primary peritoneal, vulvar, or vaginal) and undergoing chemotherapy * own a smartphone or tablet with ability to download cognitive training application * and age \>21 years old Exclusion criteria include: * medical diagnosis of dementia * significant underlying mental diagnoses for which they are on more than 1 medication for (patients with depression or anxiety on single-agent therapy will be able to participate * age \<21
Ages18 Years to 90 Years
SexFemale
Accepts healthy volunteersYes
Lead sponsorUniversity of Alabama at Birmingham
LocationsBirmingham, Alabama, United States
Start date2024-09-01
NCT IDNCT05864274
Official listinghttps://clinicaltrials.gov/study/NCT05864274

🔍 Search all trials →